Printer Friendly
The Free Library
19,607,050 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Difficulty of Achieving Regulatory Approval Hinders Atrial Fibrillation Market.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44862) has announced the addition of Datamonitor's new report: Stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property.  Insight: Atrial Fibrillation atrial fibrillation

Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection.
 - Limited Efficacy and Poor Safety Lead to Bleak Outlook to their offering.

It is estimated that there are over 11 million atrial fibrillation patients in the seven major markets. Despite high unmet needs and limitations of all the current treatment options, achievement of regulatory approval is becoming increasingly difficult. This means that a very limited number of novel treatments are expected to be introduced in the near future.

Scope of this title:

* Review of the available epidemiology epidemiology, field of medicine concerned with the study of epidemics, outbreaks of disease that affect large numbers of people. Epidemiologists, using sophisticated statistical analyses, field investigations, and complex laboratory techniques, investigate the cause  data to assess the patient population of atrial fibrillation and to segment the patient population by type

* Outline of the existing therapy options and current prescribing trends

* Assessment of the current status of the rhythm versus rate control debate and the determining factors for each type of treatment strategy

* Evaluation of the current usage of cardiac rhythm Noun 1. cardiac rhythm - the rhythm of a beating heart
heart rhythm

regular recurrence, rhythm - recurring at regular intervals

atrioventricular nodal rhythm, nodal rhythm - the normal cardiac rhythm when the heart is controlled by the
 devices and ablation ablation /ab·la·tion/ (-shun)
1. separation or detachment; extirpation; eradication.

2. removal or destruction, especially by cutting.


ab·la·tion
n.
 techniques to determine their future role in atrial fibrillation management

Highlights of this title:

The rapid increase in atrial fibrillation prevalence is driven by a number of factors, namely ageing population, the obesity epidemic, better prevention of strokes, and better survival of patients with cardiac disease.

There are numerous unmet needs associated with every treatment option available. The main unmet needs of pharmacological Pharmacological
Referring to therapy that relies on drugs.

Mentioned in: Pain Management


pharmacological, pharmacologic

pertaining to pharmacology.
 therapy are insufficient efficacy and poor safety. Non-pharmacological therapy has severe limitations, among them the cost of the procedures and the fact that a limited number of patients are eligible for it.

Despite the desperate need for a new efficacious ef·fi·ca·cious  
adj.
Producing or capable of producing a desired effect. See Synonyms at effective.



[From Latin effic
 and safe antiarrhythmic antiarrhythmic /an·ti·ar·rhyth·mic/ (-ah-rith´mik)
1. preventing or alleviating cardiac arrhythmias.

2. an agent that so acts.


an·ti·ar·rhyth·mic
adj.
, no new drug that would significantly impact atrial fibrillation management is going to appear in the nearest future.

Reasons to order your copy:

* Target physicians more effectively, through an understanding of treatment options and their prescription choices

* Assess the potential of each treatment option in the management of atrial fibrillation and understand the dynamics of the market

* Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products

For more information visit http://www.researchandmarkets.com/reports/c44862

Source: Datamonitor
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 9, 2006
Words:354
Previous Article:Potential for a Revolution in Music Rights as the Music Industry Goes Digital.
Next Article:Supportive Cancer Care Drug Market to Rise in Size and Significance.
Topics:



Related Articles
Blood thinners lower risk of stroke for some.
ERRATIC HEARTBEATS BOOST RISK OF DEATH BY STROKE.
Gene mutation causes heart problems.
Stroke in atrial fibrillation: a need for effective anticoagulation.
Altitude and atrial fibrillation.
First Patients Enrolled in St. Jude Medical's Study Looking at AF Suppression Pacing in Heart Failure Patients.
St. Jude Medical Announces FDA Approval, FDA Clearance and European CE Mark of New Electrophysiology Products; Heart Rhythm Society Meeting to...
St. Jude Medical Announces Japanese Approvals of EnSite System; Computer-based Visualization and Navigation Tool Used with Heart Rhythm Patients.
Medtronic Announces Initiation of U.S. Feasibility Trial to Evaluate Surgical Ablation Techniques to Treat Lone Atrial Fibrillation.
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles